About Professor Georgina Long

Georgina Long’s principle translational research focus is on the clinical and tissue biomarker correlates of drug therapy sensitivity and resistance in melanoma.

Georgina Long is the principle investigator for the investigator-led TEAM study (Treat, Excise and Analyse Melanoma), a large collaborative effort across Melanoma Institute Australia involving clinicians (surgery, medical oncology and pathology), cell biologists and molecular biologists. Melanoma tissue is biopsied and analysed from patients before and during treatment with novel therapies and at progression (Georgina Long PI for > 40 phase 1, 2 and 3 clinical trials in melanoma, including investigator-led trials). The TEAM study is world-recognised as the proto-type for translational research, and has significantly contributed to the design of future therapeutic strategies to improve the outcomes for patients with melanoma.

Georgina Long has a strong track record in research translation and implementation of research in melanoma, Australia's highest incident cancer. Georgina has a leadership role in development of systemic drug therapies that have taken the 1-year overall survival of patients with advanced-stage melanoma from 25-30% in 2009, to >70% in 2016, most of which are now PBS funded in Australia (both targeted- and immune-therapies). Georgina Long has also led translational research determining mechanisms of response and resistance to novel drug therapies (Long GV JCO 2011; Menzies CCR 2012). These studies and others have been critical in the design of clinical trials of combination drug therapies aiming to enhance response and decrease or delay resistance to improve patient outcomes further.

GL led the international clinical development of the BRAF inhibitor dabrafenib (Falchook-Long Lancet 2012), followed by the development of the combination of dabrafenib with the MEK inhibitor trametinib showing an unprecedented improved overall survival & quality of life (Long NEJM 2014; Long Lancet 2015). This resulted in the worldwide approval and funding of these drugs, including in Australia (on the PBS). GL was also responsible for demonstrating unparalleled activity of dabrafenib in brain metastases (Long GV Lancet Onc 2012) and activity in non-V600E BRAF mutations (Long GV JCO 2011; Menzies CCR 2012; Klein O EJC 2013), both of which have changed the course of clinical practice. GL leads research determining mechanisms of enhanced response versus resistance (Long-Wilmott CCR 2012; Rizos CCR 2014; Long Nat Comm 2015; Kakavand CCR 2015; Madore CCR 2016) to these and other drugs in development (IMMUNOTHERAPIES), data that underpins the design of current clinical trials. GL is lead medical oncologist for the development of the Australian Melanoma Management Guidelines, & has written & reviewed guidelines for oncologists e.g Evi-Q, CI NSW, & patients e.g cancer.net.

Selected publications

For a full list of publications please see Professor Long's academic profile. Click here